Northwestern sues Moderna for patent infringement over 19 vaccines
By Blake Brittain
Oct 16 (Reuters) -Moderna MRNA.O was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax.
The lawsuit said Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.
A Moderna spokesperson said the company was aware of the lawsuit and will defend itself against the claims. Attorneys and spokespeople for Northwestern did not immediately respond to a request for comment.
The lawsuit adds to a web of U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their COVID vaccines, including one brought by Moderna against Pfizer in 2022. British pharmaceutical company GlaxoSmithKline sued Moderna in the same Delaware court on Tuesday for allegedly misusing GSK's LNP technology in its COVID-19 and RSV shots.
Evanston, Illinois-based Northwestern said its researchers pioneered the use of LNPs to deliver mRNA into human cells in 2009 and 2010. The university's lawsuit said the LNPs in Moderna's Spikevax work in the same way as its patented technology.
The school's complaint said Moderna could not have made its "rapid progress" in developing the vaccine "without appropriating the technological breakthroughs of prior researchers, including those at Northwestern."
Northwestern asked the court for an unspecified amount of monetary damages from Moderna's alleged infringement including royalties. Moderna earned $6.7 billion in revenue from Spikevax last year.
The case is Northwestern University v. Moderna Inc, U.S. District Court for the District of Delaware, No. 1:24-cv-01151.
For Northwestern: Rebecca Horwitz, John Hughes, Mac LeBuhn and Katherine Rhoades of Bartlit Beck
For Moderna: Not yet available
Read more:
Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine
GSK sues Moderna for US patent infringement over COVID, RSV vaccines
Reporting by Blake Brittain in Washington
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
